base metals investing Acumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Highlights
base metals investing Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 12, 2026
base metals investing Acumen Pharmaceuticals Highlights Enhanced Brain Delivery ) Program Data and Early Alzheimer's Disease Insights at the Alzheimer's Association International Conference 2026
base metals investing Acumen Pharmaceuticals to Present Data on Enhanced Brain Delivery ) Technology and Early Alzheimer's Disease Insights at the Alzheimer's Association International Conference 2026
base metals investing Acumen Pharmaceuticals Announces Nomination of Two Enhanced Brain Delivery ) Development Candidates for the Treatment of Alzheimer's Disease
base metals investing Acumen Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Highlights
base metals investing Acumen Pharmaceuticals to Participate in the Bank of America Securities 2026 Health Care Conference
base metals investing Acumen Pharmaceuticals to Report First Quarter Financial Results on May 12, 2026
base metals investing Acumen Pharmaceuticals Highlights Enhanced Brain Delivery Technology for Oligomer-Selective Antibodies and Recruitment Strategies for Phase 2 ALTITUDE-AD Clinical Trial at 18th Annual Clinical Trials on Alzheimer's Disease Conference
base metals investing Acumen Pharmaceuticals to Present on Recruitment Strategies for Phase 2 ALTITUDE-AD Trial and Enhanced Brain Delivery Technology at 18th Annual Clinical Trials on Alzheimer's Disease Conference
Goldera Expands High-Grade E1 Gold Discovery with Two New Parallel Structures Ahead of Planned Q4 Drilling at Egan Gold Project
Oreterra CEO Letter to Shareholders Provides Forward Guidance on Trek South Drill Results in Advance of Assays
Renforth Intersects Broad Nickel-Cobalt and Zinc-Copper-Silver Mineralization in Victoria Undercut Drilling, Including 118.0 M of 0.081% Ni and 10.9 M of 0.544% Zn
